RT @HenrikVogt: New @cochranecollab publication on #ADHD and #Ritalin in children may change the field: In 1 in 100 patients"...#methylphen…
RT @HenrikVogt: New @cochranecollab publication on #ADHD and #Ritalin in children may change the field: In 1 in 100 patients"...#methylphen…
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. https://t.co/9zVwAbf91v
"Our findings suggest that methylphenidate may be associated with a number of serious adverse events as well as a large number of non-serious adverse events in children and adolescents," #ADHD https://t.co/loFVJRKlFV
RT @HenrikVogt: New @cochranecollab publication on #ADHD and #Ritalin in children may change the field: In 1 in 100 patients"...#methylphen…
RT @HenrikVogt: New @cochranecollab publication on #ADHD and #Ritalin in children may change the field: In 1 in 100 patients"...#methylphen…
RT @HenrikVogt: New @cochranecollab publication on #ADHD and #Ritalin in children may change the field: In 1 in 100 patients"...#methylphen…
La evidencia es pobre pero igualmente no se debe subestimar el riesgo de efectos adversos con el uso de metilfenidato. https://t.co/ROZqaBId4t
RT @HenrikVogt: New @cochranecollab publication on #ADHD and #Ritalin in children may change the field: In 1 in 100 patients"...#methylphen…
RT @HenrikVogt: New @cochranecollab publication on #ADHD and #Ritalin in children may change the field: In 1 in 100 patients"...#methylphen…
New @cochranecollab publication on #ADHD and #Ritalin in children may change the field: In 1 in 100 patients"...#methylphenidate might lead to SERIOUS adverse events, including death, cardiac problems, psychotic disorders." @AllenFrancesMD @DrDavidHealy ht